Inclisiran and other revenues sources | ALNY Message Board Posts


Alnylam Pharmaceuticals

  ALNY website

ALNY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34756 of 34984  at  1/17/2020 9:47:50 PM  by

Steve_382


 In response to msg 34753 by  Steve_382
view thread

Re: Inclisiran and other revenues sources

Less than two months ago, Novartis paid nearly $10 billion to acquire The Medicines Company, a deal driven by one asset, an RNAi heart drug called inclisiran. On the first day of JPM, the Swiss pharma announced ambitious plans alongside U.K. health officials to study inclisiran in a wide patient population and to ramp up manufacturing capacity for RNAi medicines.

"I believe inclisiran has the potential to be one of the largest, if not the largest, medicine at Novartis in our history," Novartis CEO Vas Narasimhan said Monday.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3  
   Views: 146 []
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...